Ocugen, Inc.

OCGN · Healthcare

$1.33

Capitalización: 451.02M USDRendimiento por dividendo: —
Advance¿Es buen momento para comprar Ocugen, Inc.? Pregunta a Copenvest AIObtén una lectura Advance con IA sobre timing, riesgo y qué hacen los inversores rastreados.Preguntar a Copenvest AI

Cargando gráfico…

Noticias

Últimos titulares de esta acción

GlobeNewswire Inc.25 ago 2026, 11:02

Ocugen to Participate in Upcoming September Investor and Industry Conferences

Ocugen, Inc. announced it will present its innovative modifier gene therapy platform at three major conferences in September 2026, including the Citi Biopharma Back to School Conference, H.C. Wainwright Global Investment Conference, and The Retina Society Annual Scientific Meeting. The company will showcase 12-month Phase 2 results for OCU410 gene therapy for geographic atrophy.